EICHORCondition: Advanced Squamous Tumors · Sponsor: AbbVie
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in combination with budigalimab (ABBV-181) in adults with advanced squamous tumors. ABBV-711 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-711 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 220 adult participants will be enrolled in the study across 40 sites worldwide. In part 1, oral ABBV-711 tablets will be given in escalating doses alone to participants with squamous (sq) tumors. In part 2 oral ABBV-711 tablets will be given at a selected dose from part 1 to participants with squamous non-small cell lung cancer (sqNSCLC), or head and neck squamous cell carcinoma (HNSCC). In part 3, oral ABBV-711 tablets will be given in escalating doses in combination with intravenously (IV) infused budigalimab to participants with sq tumors. In part 4 oral ABBV-711 tablets will be given at a selected dose from part 3 in combination with IV infused budigalimab to participants with sqNSCLC, or HNSCC. The estimated duration of the study is up to approximately 5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Part…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| City Of Hope Comprehensive Cancer Center /ID# 276550 | Duarte, California, United States | Recruiting |
| City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432 | Irvine, California, United States | Recruiting |
| University of Chicago Medical Center /ID# 276638 | Chicago, Illinois, United States | Recruiting |
| START Midwest /ID# 272505 | Grand Rapids, Michigan, United States | Recruiting |
| Carolina BioOncology Institute /ID# 272380 | Huntersville, North Carolina, United States | Recruiting |
| Next Oncology - Irving /ID# 276659 | Irving, Texas, United States | Recruiting |
| Princess Margaret Cancer Centre /ID# 276852 | Toronto, Ontario, Canada | Recruiting |
| The Chaim Sheba Medical Center /ID# 276798 | Ramat Gan, Tel Aviv, Israel | Recruiting |
| Rambam Health Care Campus- Haifa /ID# 276799 | Haifa, Israel | Recruiting |
| Hadassah Medical Center-Hebrew University /ID# 276800 | Jerusalem, Israel | Recruiting |
| National Cancer Center Hospital East /ID# 276585 | Kashiwa-shi, Chiba, Japan | Recruiting |
| Kansai Medical University Hospital /ID# 276586 | Hirakata-shi, Osaka, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07241039